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Introduction {#sec005}
============

Soil-transmitted helminth (STH) infections affect approximately 2 billion persons worldwide \[[@pntd.0003590.ref001]\], with school-aged children generally having the highest-intensity infections and highest prevalence of infection \[[@pntd.0003590.ref002]--[@pntd.0003590.ref006]\]. Improper disposal of human feces contaminated with helminth eggs exposes humans to infection following ingestion of eggs (*Trichuris trichura*, or whipworm, and *Ascaris lumbricoides*, or roundworm) or skin contact with larvae that hatch from eggs (*Ancystoloma duodenale* and *Necator americanus*, or hookworm). A wide array of physical effects have been attributed to intestinal STH infections, including anemia (primarily from hookworm infection) \[[@pntd.0003590.ref007]--[@pntd.0003590.ref009]\], Vitamin A deficiency \[[@pntd.0003590.ref010]\], decreased physical fitness \[[@pntd.0003590.ref011]\], decreased cognitive function \[[@pntd.0003590.ref012], [@pntd.0003590.ref013]\], decreased growth \[[@pntd.0003590.ref012], [@pntd.0003590.ref014]--[@pntd.0003590.ref016]\], and intestinal obstruction \[[@pntd.0003590.ref017]\]. Morbidity is directly related to infection intensity \[[@pntd.0003590.ref018]\].

Without meaningful improvements in sanitation infrastructure in low-resource settings, elimination of STH infections is likely not feasible. Because of this, and because most morbidity is attributable to high- and moderate-intensity infections, the World Health Organization (WHO) recommends, rather than elimination, reduction of worm burden in individuals \[[@pntd.0003590.ref019]\]. In 2001, WHO set the goal of providing regular preventive deworming chemotherapy to at least 75% of at-risk school-aged children by 2010, and urged endemic countries to develop programs to administer these drugs through schools and primary healthcare systems \[[@pntd.0003590.ref020]\]. In 2012, pharmaceutical companies GlaxoSmithKline and Johnson & Johnson agreed to donate billions of doses of anthelminthic drugs to countries in need \[[@pntd.0003590.ref021]\], enabling the expansion of existing government-sponsored deworming programs, most of which have not yet reached the 75% target.

Many STH-endemic countries, including Kenya, are now planning or actively implementing national school-based deworming programs, provided as mass drug administration (MDA) conducted by Ministries of Health, Ministries of Education, and nongovernmental organization (NGO) partners \[[@pntd.0003590.ref022]\]. Based on STH prevalence mapping and spatial modeling in Kenya \[[@pntd.0003590.ref023]--[@pntd.0003590.ref025]\], a phased-in approach to school-based deworming was planned for selected districts in five of the country's eight provinces, excluding Nairobi, Rift Valley, and North Eastern Provinces \[[@pntd.0003590.ref022], [@pntd.0003590.ref026]\]; this program is in the process of being implemented \[[@pntd.0003590.ref026]\]. However, smaller-scale deworming programs are also frequently carried out by other in-country partners \[[@pntd.0003590.ref027]\], who may use different regimens for deworming. In addition, deworming drugs are widely available from clinics, drugstores, and other sources. This 'unprogrammed deworming'---deworming outside of the context of a nationally-administered STH control program---is frequently neither documented nor reported to health officials \[[@pntd.0003590.ref027]\].

There is currently great interest in evaluating the effectiveness of national deworming MDA programs and progress towards the WHO treatment coverage targets for 2020 \[[@pntd.0003590.ref028]--[@pntd.0003590.ref031]\]. However, accurate reporting of deworming is required to monitor this progress. The unknown extent and patterns of unprogrammed deworming challenge both the monitoring and evaluation of STH control programs. We describe unprogrammed deworming in Kibera, an urban slum in Nairobi, Kenya. Nairobi is not included in the national deworming program, due to an overall low prevalence of STH infection \[[@pntd.0003590.ref032]\].

Methods {#sec006}
=======

This study was conducted in two villages of Kibera, Kenya, during April---June 2012 as part of a larger cross-sectional evaluation of STH infection and nutritional status in children enrolled in the Centers for Disease Control and Prevention's (CDC) International Emerging Infections Program (IEIP)/Kenya Medical Research Institute (KEMRI) surveillance platform. Details of this study are provided elsewhere \[[@pntd.0003590.ref033]\]. In brief, IEIP enrolls all adults and children with head-of-household consent who have been living in all households in the two-village study area continuously for at least four months. Among households in the IEIP participant registry, approximately 25% were designated as potential sources for enrollment of preschool-aged children (PSAC) (aged 12--59 months) and infants (aged 6--11 months). The other 75% of households were designated as potential sources for enrollment of school-aged children (SAC) (aged 5--14 years); this ensured that two children were not selected from the same household. Households were selected with probability proportional to size from each target group, and one child was chosen randomly from each selected household. Up to three stools were collected from all selected children and tested by Kato-Katz analysis as described previously \[[@pntd.0003590.ref033]\]. Field workers visited households and, using a visual recall aid showing the locally-available deworming medicines, asked parents about whether or not their SAC or PSAC had been dewormed in the past year, and the source of their deworming medication the last time they were treated in the past year. In addition, parents provided information on the school attended by the child. Schools were defined as 'public' (under the purview of the Ministry of Education), 'private' (privately-owned and operated, following public curricula), or 'informal' (not under the purview of the Ministry of Education and with independent curricula).

Because responses suggested that many children were receiving deworming medication at school, administrators and teachers were interviewed at five schools attended by children in the survey. These semi-structured interviews included questions about previous deworming and other health interventions that took place at the school (frequency of interventions, medications administered, and deworming partners). Information from these interviews was used to identify organizations providing deworming treatments in schools in this area. These organizations were subsequently contacted and asked to share any available deworming records from 2010--2012, including school name, school type and location, date of deworming event(s), enrollment figures, and treatment figures. Only 2012 data are included in this report. Drug coverage was estimated by dividing the number of doses of deworming medication reported to have been distributed at each deworming event by the total school enrollment at the time of deworming. Proportions were compared using chi-squared or Fisher's exact test, where appropriate; missing data were excluded. Data were analyzed in SAS 9.3 (English).

Ethics statement {#sec007}
----------------

This study was approved by Institutional Review Boards at the Kenya Medical Research Institute (KEMRI) and the U.S. Centers for Disease Control and Prevention (CDC). Written informed parental or guardian consent was required for all participants. Written assent was additionally obtained from all participants aged 13 years or older.

Results {#sec008}
=======

Self-reported deworming {#sec009}
-----------------------

Of the 692 children included in the initial study, 679 had data on past-year deworming, including 18 infants, 184 PSAC, and 477 SAC. Of the 679, 377 (55.5%) reported receiving deworming drug treatments during the previous year. Past-year deworming occurred approximately equally among PSAC (62.0%) and SAC (54.1%) (p = 0.07), a median of three months (range, 0--12 months) before the interview for both groups. Five (27.7%) infants received deworming medication during the previous year. We examined frequency of past-year deworming by one- and two-year age categories; when infants were excluded, there were no differences between these age groups (p = 0.12) ([Fig. 1](#pntd.0003590.g001){ref-type="fig"}).

![Proportion of children in each age group whose parents reported that they had been dewormed at least once during the previous year, Kibera, Kenya, 2012.\
Numbers in parentheses represent denominators for each age group.](pntd.0003590.g001){#pntd.0003590.g001}

Among the 377 children dewormed during the previous year, the most common source of the most recent deworming medication was school (39.5%), a chemist (independently-owned commercial drug kiosks) (27.9%), or a clinic/hospital or health center (26.3%) ([Table 1](#pntd.0003590.t001){ref-type="table"}). Among PSAC who were dewormed, the chemist (48.3%) and clinic/hospital or health center (37.7%) were the most common source of deworming medications; most SAC who were dewormed (55.0%) received the drugs at school. The five infants who were dewormed received drugs from a clinic/hospital or health center.

10.1371/journal.pntd.0003590.t001

###### Sources of drugs for the most recent deworming, overall and by child type, among children who were reported as taking deworming medications at least once during the past year, Kibera, Kenya, 2012.

![](pntd.0003590.t001){#pntd.0003590.t001g}

                                               Overall (n = 377)   Infants (n = 5)   PSAC (n = 114)   SAC (n = 258)
  -------------------------------------------- ------------------- ----------------- ---------------- ---------------
  **School**                                   149 (39.5%)         0                 7 (6.1%)         142 (55.0%)
  **Chemist**                                  105 (27.9%)         0                 55 (48.3%)       50 (19.4%)
  **Clinic / hospital / health center**        99 (26.3%)          5 (27.8%)         43 (37.7%)       51 (19.8%)
  **Medical camp (traveling health clinic)**   12 (3.2%)           0                 4 (3.5%)         8 (3.1%)
  **Individual mobile vendor**                 7 (1.9%)            0                 3 (2.6%)         4 (1.6%)
  **Other**                                    5 (1.3%)            0                 2 (1.8%)         3 (1.2%)

School-based deworming of school-aged children in Kibera {#sec010}
--------------------------------------------------------

Of the 477 SAC, 442 (92.7%) normally spent the day at school, while 85 (46.2%) of the 184 PSAC spent the day at a nursery school or early childhood learning center. At least 150 different schools were named by respondents as being attended by the SAC included in our study; school name was not recorded for eight SAC. Of the 71 schools for which data were available, 45 (63.4%) were informal, 16 (22.5%) were private, and 10 (14.1%) were public. Of the 393 school-aged children with data on schools attended, 194 (49.4%) attended a public school, 140 (35.6%) attended an informal school, and 59 (15.0%) attended a private school.

Among 383 SAC with data on both school type and deworming, those who attended a public school were more likely to have taken deworming drugs in the past year (from any source) (120/190, 63.2%) than children who attended a private school (29/58, 50.0%)(p = 0.07) or an informal school (61/135, 45.2%) (p = 0.001). Among all SAC who were dewormed, public-school children were non-statistically-significantly more likely to have received their most recent deworming medications at school (78/120, 65.0%) than private-school children (16/29, 55.2%) or children attending an informal school (30/61, 49.2%) (p = 0.11).

Of the 679 children in this analysis, 268 (39.5%) were infected with at least one STH, including *Trichuris* (n = 176; 25.9%), *Ascaris* (n = 156; 23.0%), and hookworm (n = 1; \<1%). Past-year deworming was associated with reduced frequency of any STH infection (34.8% vs. 45.4%, p = 0.005). When data were limited to the three most common sources of deworming medications (school, chemist, and clinic/hospital/health center), SAC whose most recent deworming medication was sourced from a chemist were more frequently infected with *Trichuris* (19/50, 38.0%) than those whose most recent deworming medication was obtained from a clinic/hospital/health center (9/52, 17.3%) or school (33/143, 23.1%) (p = 0.05). The presence of other STH infections and any STH infection were not significantly different by treatment source among SAC or PSAC.

NGO deworming of schools {#sec011}
------------------------

Four NGOs were identified as providing school-based deworming medications to children in our study area and were contacted for follow-up. Local government in Nairobi County had partnered with one of these NGOs to deworm children at selected schools (independent from the Kenyan national school-based deworming program); the other three NGOs worked independently from the government and directly with schools. The NGOs reported deworming at 47 schools in Kibera during 2012; 44 (93.6%) schools received deworming treatment once and three were dewormed twice (a total of 50 deworming events). Of the schools with two deworming events during 2012, two had both events administered by the same NGO, and one received deworming treatments from two different NGOs, during February and December 2012. Calculated deworming coverage among enrolled pupils at these events ranged from 72%--130% (median 98.7%). Of 31 schools with data on school type, 19 were informal, eight were public, and four were private.

Discussion {#sec012}
==========

Unprogrammed deworming, defined as treatment with deworming drugs outside the context of a nationally-administered STH program, is increasingly recognized in many areas that are endemic for STH infections. Our data indicate that more than half of all preschool- and school-aged children in two villages of the informal settlement of Kibera, Kenya received unprogrammed deworming treatments during 2012. These treatments were obtained from a wide variety of sources, which differed by age group: while school-aged children most often obtained treatments in school, frequently through the efforts of NGOs, preschool-aged children more often received treatments from independent suppliers, such as clinics and chemist shops. The median time since last deworming was three months, suggesting that children may be treated several times each year. Because our survey questions were designed to identify only the most recent source of deworming medication, these data likely underestimate the true frequency of unprogrammed deworming events.

Although unprogrammed deworming is rarely reported, it is likely widespread. A recent evaluation of MDA in Bangladesh described high levels of unprogrammed deworming among school-aged children living in an area already receiving programmed school-based deworming \[[@pntd.0003590.ref034]\]. The relatively low cost of such drugs also enhances their accessibility \[[@pntd.0003590.ref034], [@pntd.0003590.ref035]\]: at the local medical clinic in Kibera, albendazole and mebendazole cost approximately \$0.02 USD for a single mebendazole tablet to approximately \$0.22 USD for albendazole suspension (O. Mogeni, personal communication). Although individual-level deworming is indicated in specific circumstances, such as for children with palmar pallor in Integrated Management of Childhood Illness (IMCI) programs \[[@pntd.0003590.ref036], [@pntd.0003590.ref037]\] or in certain maternal health settings, mass unprogrammed deworming, when carried out in an area that already has programmed deworming, may represent wasted treatment in areas with already-limited resources.

In addition to the potential for wasted treatments, unprogrammed deworming may complicate evaluations of effectiveness of nationally-implemented STH control programs. Nonreporting of deworming events to Ministries of Health or to WHO, as previously reported, \[[@pntd.0003590.ref027]\], compromises the monitoring of progress towards WHO-recommended anthelmintic coverage targets \[[@pntd.0003590.ref018],[@pntd.0003590.ref020]\]. Typically, changes in prevalence and intensity of STH infection are assumed to be due to the effectiveness of drugs delivered through programmed MDAs \[[@pntd.0003590.ref038]--[@pntd.0003590.ref042]\], occasionally in combination with improvements in sanitation or hygiene \[[@pntd.0003590.ref043]\]. However, high levels of unprogrammed treatment may inflate the apparent effectiveness of programmed MDA. In our study, 55% of children received unprogrammed deworming drugs, a proportion not far below the 75% coverage target set by the WHO \[[@pntd.0003590.ref020]\]. Unprogrammed deworming at this level would almost certainly have an impact on the evaluated effectiveness of a nationally-run MDA program. While the mutual influences of unprogrammed deworming and programmed MDA on each other's administration frequencies are unknown, in the Bangladesh study, unprogrammed deworming continued at a high rate despite the presence of a national school-based deworming program: 38.7% (95% CI 51.9--64.4) of school-aged children living in a district already receiving two programmed school-based deworming events during 2009 \[during which surveyed coverage was 52.3% (95% CI 43.6--61.1%) and 54.3% (95% CI 44.8--63.8%)\] reported that they had additionally obtained deworming drugs during that year from other, non-school sources \[[@pntd.0003590.ref034]\]. The lack of coordinated timing of these unprogrammed treatments, even where \>1 treatment per year is appropriate (for example, in very high STH-prevalence settings) \[[@pntd.0003590.ref018]\], could also influence their effectiveness.

The effectiveness of unprogrammed deworming on the control and transmission of STH infections is unclear. Nairobi is not considered a high-prevalence region for STH infections \[[@pntd.0003590.ref032]\], and therefore Kibera is not included in the Kenyan national school-based deworming program. Receipt of unprogrammed deworming was associated with reduced STH infection in our study area, and heavy infections were very rare \[[@pntd.0003590.ref033]\]; this may be due in part to the unprogrammed deworming events reported by participants. However, unprogrammed deworming may expose infected individuals to drugs of suboptimal quality \[[@pntd.0003590.ref041]\]. Our data indicated that school-aged children who received their most recent deworming treatment from a chemist were more likely to be infected with *Trichuris spp* than those who obtained their treatment from a clinic or at school. While this may reflect the use of different (and variably effective) drug brands or drug qualities---for example, levamisole, widely available in this setting, is less effective against *Trichuris spp* than albendazole or mebendazole \[[@pntd.0003590.ref044]\], and its use in individual but not school-based deworming may have led to these differences---it may also be reflective of the spectrum of reasons individuals take deworming medications. For example, drugs at school may have been administered as MDA, without regard to actual infection status, while drugs from chemists may have been purchased with the intention of treating a known infection. If this is indeed the case, children whose parents purchased drugs from the chemist may be at higher risk for infection. Information about how and why parents obtain deworming medications for their children outside of MDA would be useful in answering these questions.

Beyond the potential individual effects of suboptimal treatment, use of suboptimal drugs on a population level may promote the selection of worms resistant to anthelminthic treatments \[[@pntd.0003590.ref041], [@pntd.0003590.ref045]\]. Veterinary data demonstrate the rapid spread of benzimidazole resistance in animal populations treated with the drug (reviewed in \[[@pntd.0003590.ref045]\]). While there are few data to suggest that anthelminthic resistance is a widespread problem in humans at present, our inability to accurately determine the true frequency of deworming makes it more difficult to monitor drug efficacy and assess the potential for anthelminthic resistance \[[@pntd.0003590.ref046]\]. Surveys of medications available and doses recommended by chemists would provide information on the occurrence and frequency of suboptimal drug treatment, and allow for opportunities to correct common problems.

As indicated from our data, in addition to NGO- and other-entity-driven deworming, individual treatment may also be common. Although reporting of individual treatment is impractical, individual treatment may prove particularly important in the'endgame' of STH control, when STH infections may still be present, but at too low a prevalence to warrant MDA \[[@pntd.0003590.ref018]\]. In such settings, continued suppression of STH transmission will likely require the availability of high-quality and low-cost deworming drugs, health-seeking behavior to access these drugs on an individual basis, and improved sanitation and hygiene. In addition, individual treatment will remain important for infected subpopulations who often are not targeted for routine STH treatment, such as adult men, and, currently, women of child-bearing age, who are at increased risk of hookworm-related anemia \[[@pntd.0003590.ref047]--[@pntd.0003590.ref049]\]. Understanding the factors that drive self-treatment can serve to prepare public health officials for the STH'endgame.'

Despite the challenges associated with unprogrammed deworming, it currently fills a need in places where programmed deworming is not occurring. Although Nairobi is not eligible for school-based MDA due to its overall low prevalence of STH infection in school-aged children, Kibera, an impoverished slum inside the city limits, clearly represents a pocket of high prevalence of STH infection, likely due to its very poor water quality and poor sanitation \[[@pntd.0003590.ref050]\]. For school-aged children in this area, the unprogrammed deworming carried out by the local government in partnership with NGOs fills an otherwise unmet need. In addition, for preschool-aged children in Kibera, there is no programmed treatment, including MDA to treat lymphatic filariasis (although IMCI deworming guidelines are implemented in clinical settings) \[[@pntd.0003590.ref037]\]. Unprogrammed treatment partially fills this gap, at no cost to national governments. It is important to encourage further understanding of how, how much, and why unprogrammed treatment occurs, to assist in evaluating its contribution to STH control both inside and outside the context of national STH control programs.

To this end, the STH community must develop validated, comprehensive, and flexible tools to evaluate the frequency, source, and impact of unprogrammed deworming received whenever MDA coverage or effectiveness surveys are implemented. These tools should include questions about the number of times deworming medication was received outside of the context of MDA during the past year, where the drug was sourced from (if known), the type of drug obtained, and, among persons who choose to obtain their own deworming medications, when and why they opted to do so. Sources of drugs provided by NGOs should also be investigated and a sample of locally-available deworming medications tested, to evaluate their effectiveness at delivering the promised results. Different approaches may be required in different settings to confirm the extent of unprogrammed deworming and the source of drugs for different target groups. The variety of drug sources and informants involved in providing and reporting unprogrammed deworming adds a layer of complexity to its accurate assessment. It was not possible in our study to ascertain the veracity of parent-reported deworming; it is possible that other locally-available (and perhaps locally specific) deworming medication sources exist, and setting-specific tools should be developed to assess these during formal evaluations of STH MDA programs, perhaps including components of record review from NGOs and schools as well as individual recall.

In addition to possible recall challenges, potential limitations to our analysis include drug misclassification by respondents: what respondents thought was a deworming drug may have been something else, and what they thought was a drug for a different purpose may have been an anthelminthic. Future studies should verify agreement between the answer to deworming questions without visual aids and the answer when mothers are shown the different deworming drugs and preparations available in the area and asked which one, if any, their child received. In addition, this study took place in an area where a national government-sponsored deworming program was not occurring; were such a program taking place, the frequency of unprogrammed deworming, particularly by NGOs partnering with local government, might have been lower. However, non-school-based receipt of deworming medications accounted for approximately 60% of deworming drugs in this study, suggesting that individual deworming might continue. Partially as a result of the findings in this study, there are now discussions about implementing school-based anthelminthic MDA as part of the national program in parts of Nairobi. Should this occur, a repeat of this evaluation at that time will help shed light on the frequency of unprogrammed treatment while national government-sponsored MDA is occurring. Finally, as an urban African slum, Kibera is unusual in that it serves as a setting for multiple studies and NGO-based interventions. Due to the abundance of NGOs in Kibera, children living there may be more likely to have received NGO-sponsored unprogrammed deworming compared with children living in other urban slums.

In summary, unprogrammed deworming is substantial in Kibera, Kenya. Anecdotal and limited published evidence suggests that unprogrammed deworming is both prevalent and widespread. STH control programs must develop ways to determine the extent, impact, and patterns of unprogrammed deworming to inform guidelines and rational approaches to STH control.
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